Iran Produces “Tocilizumab” Domestically

Tuesday, July 28, 2020 - 09:44
Tocilizumab  or Actemra

An official with Food and Drug Administration has announced that the drug “Tocilizumab”, confirmed to be effective in the coronavirus treatment, has been produced in Iran and will be distributed in hospitals by the next two weeks.

According to an IRNA report, Heydar Mohammadi stated that in addition to Remdesivir, Tocilizumab has been approved by the U.S. Food and Drug Administration to help partially improve COVID-19.

This drug has not yet entered the pharmaceutical market in the country and only a limited amount of it had previously been donated to China, which is still used in hospitals, he stated, Tehran Times reports.

He went on to say that the subcutaneous injection of Tocilizumab or Actemra, which is used to treat rheumatism, is now produced by an Iranian pharmaceutical company, but the intravenous injection is used for COVID-19 patients.

Probably next week, the clinical trials and tests will be approved by the Food and Drug Administration, and it will most likely be released and distributed in the hospitals during the next two weeks, he noted.

Iran previously produced the antiviral agent remdesivir for the treatment of coronavirus patients.


Popular News

Latest News